Luigi Colombo has a degree in Chemistry and Pharmaceutical Technologies, he is adjunct professor at the Department of Drug Science, State University of Milan (Italy), and author of several patents and publications.
He has more than 30 years in R&D and operations in large pharmaceutical companies with executive positions (Marion Merrell Dow, Hoechst Marion Roussell, Boeringer Ingelheim, Biosearch Italia, Serono, Merck Group); in 1996 Luigi Colombo co-founded Biosearch Italia, an Italian biotech company listed at the Nuovo Mercato, merged with Versicor, went public on the Nasdaq (changing its name in Vicuron Pharmaceuticals Inc.), and acquired (ca. USD 1.9 billion) by Pfizer in 2005. Luigi left Merck, where he was VP and Managing Director, in mid-2018. He currently works as an independent consultant. He is the CEO (pro tempore) of SilverAid, a MedTech startup company focused on dentistry. Moreover, is a director of the board at Nocturnal Lab SpA, a seed investment fund.